JP2021525726A5 - - Google Patents

Info

Publication number
JP2021525726A5
JP2021525726A5 JP2020566627A JP2020566627A JP2021525726A5 JP 2021525726 A5 JP2021525726 A5 JP 2021525726A5 JP 2020566627 A JP2020566627 A JP 2020566627A JP 2020566627 A JP2020566627 A JP 2020566627A JP 2021525726 A5 JP2021525726 A5 JP 2021525726A5
Authority
JP
Japan
Prior art keywords
composition according
immunogenic product
pharmaceutical composition
allergic
disease
Prior art date
Application number
JP2020566627A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019229153A5 (https=
JP2021525726A (ja
JP7291729B2 (ja
Filing date
Publication date
Priority claimed from EP18305651.4A external-priority patent/EP3574915A1/en
Application filed filed Critical
Publication of JP2021525726A publication Critical patent/JP2021525726A/ja
Publication of JP2021525726A5 publication Critical patent/JP2021525726A5/ja
Publication of JPWO2019229153A5 publication Critical patent/JPWO2019229153A5/ja
Priority to JP2023092544A priority Critical patent/JP2023110045A/ja
Application granted granted Critical
Publication of JP7291729B2 publication Critical patent/JP7291729B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566627A 2018-05-29 2019-05-29 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物 Active JP7291729B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023092544A JP2023110045A (ja) 2018-05-29 2023-06-05 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862677290P 2018-05-29 2018-05-29
EP18305651.4A EP3574915A1 (en) 2018-05-29 2018-05-29 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
EP18305651.4 2018-05-29
US62/677,290 2018-05-29
EPPCT/EP2019/050154 2019-01-04
PCT/EP2019/050154 WO2019228674A1 (en) 2018-05-29 2019-01-04 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il-13 expression or activity
PCT/EP2019/064025 WO2019229153A2 (en) 2018-05-29 2019-05-29 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023092544A Division JP2023110045A (ja) 2018-05-29 2023-06-05 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物

Publications (4)

Publication Number Publication Date
JP2021525726A JP2021525726A (ja) 2021-09-27
JP2021525726A5 true JP2021525726A5 (https=) 2022-06-03
JPWO2019229153A5 JPWO2019229153A5 (https=) 2022-06-03
JP7291729B2 JP7291729B2 (ja) 2023-06-15

Family

ID=62631036

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566627A Active JP7291729B2 (ja) 2018-05-29 2019-05-29 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物
JP2023092544A Pending JP2023110045A (ja) 2018-05-29 2023-06-05 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023092544A Pending JP2023110045A (ja) 2018-05-29 2023-06-05 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物

Country Status (15)

Country Link
US (2) US12059457B2 (https=)
EP (3) EP3574915A1 (https=)
JP (2) JP7291729B2 (https=)
KR (2) KR102871378B1 (https=)
CN (1) CN112423784B (https=)
AU (2) AU2019276173B2 (https=)
BR (1) BR112020024308A2 (https=)
CA (1) CA3101702A1 (https=)
CU (1) CU20200091A7 (https=)
IL (2) IL278898B2 (https=)
MA (1) MA52748A (https=)
MX (2) MX421649B (https=)
SG (1) SG11202011528UA (https=)
WO (2) WO2019228674A1 (https=)
ZA (1) ZA202007264B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Ｉｌ１３を含む融合タンパク質
EP3845556A1 (fr) * 2019-12-31 2021-07-07 Peptinov SAS Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6
WO2023021195A1 (en) * 2021-08-20 2023-02-23 Neovacs mRNA VACCINES COMPRISING IL-4 AND/OR IL-13 RNA AND USES THEREOF

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US646A (en) 1838-03-21 Improvement in furnaces for smelting iron with anthracite
US6207A (en) 1849-03-20 Improved spriing snap-hook
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5769047A (en) 1991-12-23 1998-06-23 Zoche; Michael Engine with oil separator
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
ATE378066T1 (de) 1998-09-30 2007-11-15 Wyeth Corp Mutiertes cholera holotoxin als hilfsmittel
KR100898648B1 (ko) 2001-06-07 2009-05-22 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
CA2449670A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
WO2003040164A2 (en) 2001-11-07 2003-05-15 Cytos Biotechnology Ag Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases
JP2006503017A (ja) 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
JP2006503018A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
CA2562642A1 (en) * 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of multiple vaccines
US20070224205A1 (en) * 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
CN100558747C (zh) * 2006-04-06 2009-11-11 海南天源康泽医药科技有限公司 以白喉毒素突变体crm197为载体的免疫原及其制备方法与应用
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
MX2013011201A (es) 2011-03-29 2013-12-16 Immunogen Inc Proceso para la elaboracion de conjugados de mejor homogeneidad.
CA2832260C (en) * 2011-04-07 2021-06-22 Neovacs Method for treating ifnalpha related conditions
CA2835018C (en) * 2011-05-04 2020-04-21 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
CN102807621B (zh) * 2011-06-01 2016-04-13 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
DE202013011988U1 (de) 2012-05-15 2015-04-01 Rajesh Shah Entzündungshemmende Rezeptur
PL2668959T3 (pl) * 2012-05-31 2015-04-30 Innavirvax Związki immunogenne zawierające peptyd HIV gp41 sprzężony z białkiem nośnikowym CRM197
AR101455A1 (es) * 2014-08-05 2016-12-21 Glaxosmithkline Biologicals Sa Molécula portadora
CN109890408A (zh) * 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2021525726A5 (https=)
JP6464384B2 (ja) キナーゼ阻害剤
JP6662863B2 (ja) Ｐ３８キナーゼ阻害剤としての４−（４−（４−フェニルウレイドナフタレン−１−イル）オキシピリジン−２−イル）アミノ安息香酸誘導体
JP2020514333A5 (https=)
CN113264921B (zh) 作为激酶抑制剂的吡唑基-脲
JP2020537657A5 (https=)
TW200523250A (en) Compounds for inflammation and immune-related uses
JP2013526609A5 (https=)
JP2014507455A5 (https=)
JP2009532417A5 (https=)
JP2016511753A5 (https=)
JP2021500403A5 (https=)
JP2019535761A5 (https=)
JP2013525420A5 (https=)
JP2019537577A5 (https=)
JPWO2019229153A5 (https=)
RU2020138620A (ru) Иммуногенный продукт, содержащий il-4 и/или il-13 для лечения нарушений, ассоциированных с аберрантной экспрессией или активностью il-4 и/или il-13
RU2023132215A (ru) Иммуногенный продукт, содержащий il-4 и/или il-13 для лечения нарушений, ассоциированных с аберрантной экспрессией или активностью il-4 и/или il-13
ES2204171T3 (es) Derivados de furopiridina y su utilizacion terapeutica.
WO2014117700A1 (zh) 一种原人参二醇衍生物、其制备方法及其应用
JP2017514842A (ja) 多形形態の［５−フルオロ−３−（｛２−［（４−フルオロベンゼン）スルホニル］ピリジン−３−イル｝メチル）−２−メチルインドール−１−イル］−酢酸
JP2020536972A5 (https=)
JP2017514841A5 (https=)
RU2016107798A (ru) Ингалируемые частицы, содержащие тиотропий и индакатерол
JP2021534110A5 (https=)